Injecting Immunotherapy Directly Into the Brain Spine Fluid Shows Promise for Deadly Cancer Stage
A phase 1 trial finds intraventricular nivolumab is safe for leptomeningeal metastases, with median survival of 6.6 months.
Summary
Leptomeningeal disease — when cancer spreads to the fluid-filled membranes surrounding the brain and spinal cord — is one of the most devastating and treatment-resistant cancer stages. A multicenter phase 1 trial tested whether nivolumab, a checkpoint inhibitor immunotherapy, could be delivered directly into the brain's ventricular system rather than intravenously. Thirty patients with various solid tumors were enrolled, and 24 received at least one dose across four escalating dose levels. The trial met its primary safety endpoint, with only one dose-limiting toxicity observed. The recommended dose for the ongoing expansion phase is 50 mg. Median overall survival was 6.6 months, with 33% of patients alive at one year. Quality of life remained stable throughout treatment, a meaningful finding in this population.
Detailed Summary
Leptomeningeal metastatic disease occurs when cancer cells spread into the cerebrospinal fluid and meninges — the membranes enveloping the brain and spinal cord. It represents one of the most treatment-resistant and rapidly fatal cancer stages, with median survival historically measured in weeks to a few months. There is profound unmet need for novel therapeutic approaches in this setting.
The IT-PD1/NOA-26 trial is a multicenter phase 1 study investigating whether nivolumab — a PD-1 checkpoint inhibitor already approved intravenously for multiple cancers — can be administered directly into the cerebral ventricles via an intraventricular reservoir. This route of administration aims to achieve therapeutic drug concentrations within the central nervous system compartment, bypassing the blood-brain barrier that limits systemic drug delivery.
Thirty patients with leptomeningeal disease from solid tumors eligible for PD-1/PD-L1 therapy or with high tumor mutational burden were enrolled. Dose escalation proceeded across four cohorts: 20, 30, 40, and 50 mg. Of 24 patients who received at least one dose, 18 completed predefined safety evaluations. Only one dose-limiting toxicity occurred, at the 40 mg level. The primary safety endpoint was met, and 50 mg was selected as the recommended dose for the ongoing expansion phase.
Survival outcomes were encouraging in context: median overall survival was 6.6 months, with 55% alive at six months, 33% at twelve months, and 17% at eighteen months. Crucially, participant-reported quality of life remained stable throughout treatment — a finding of considerable importance given that maintaining function and comfort is a central goal in this population.
The trial now advances to its expansion phase. Caveats include the small sample size inherent to phase 1 dose-escalation design, the absence of a control arm, and that this summary is based on the abstract only, with full data not yet accessible. Nonetheless, the safety profile and survival signals are notable for a condition historically associated with survival measured in weeks.
Key Findings
- Intraventricular nivolumab met safety endpoints across four dose levels; 50 mg selected for expansion phase.
- Median overall survival was 6.6 months — substantially longer than historical benchmarks for leptomeningeal disease.
- One-year survival rate was 33%, with 17% of patients alive at 18 months.
- Quality of life remained stable throughout treatment, critical for this severely ill population.
- Only one dose-limiting toxicity observed across 24 treated patients, suggesting manageable safety profile.
Methodology
This is the dose-escalation component of a multicenter phase 1 trial (NCT05112549) enrolling adults with leptomeningeal metastases from solid tumors approved for systemic PD-1/PD-L1 therapy or with high tumor mutational burden. Nivolumab was administered intraventricularly at 20, 30, 40, and 50 mg, with independent data safety monitoring board review before each escalation. Primary endpoint was safety; secondary endpoint was overall survival.
Study Limitations
This is a small phase 1 dose-escalation trial without a control arm, limiting causal interpretation of survival outcomes. The full dataset, including detailed adverse event profiles and exploratory endpoints, was not available as this summary is based on the abstract only. Results may not generalize beyond tumor types eligible for PD-1/PD-L1 therapy.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.